Literature DB >> 24576790

Obsessive-compulsive disorder.

Gyula Bokor1, Peter D Anderson.   

Abstract

Obsessive-compulsive disorder (OCD) is a common heterogeneous psychiatric disorder manifesting with obsessions and compulsions. Obsessions are intrusive, recurrent, and persistent unwanted thoughts. Compulsions are repetitive behaviors or mental acts that an individual feels driven to perform in response to the obsessions. The heterogeneity of OCD includes themes of obsessions, types of rituals, presence or absence of tics, etiology, genetics, and response to pharmacotherapy. Complications of OCD include interpersonal difficulties, unemployment, substance abuse, criminal justice issues, and physical injuries. Areas of the brain involved in the pathophysiology include the orbitofrontal cortex, anterior cingulate gyrus, and basal ganglia. Overall, OCD may be due to a malfunction in the cortico-striato-thalamo-cortical circuit in the brain. Neurotransmitters implicated in OCD include serotonin, dopamine, and glutamate. Numerous drugs such as atypical antipsychotics and dopaminergic agents can cause or exacerbate OCD symptoms. The etiology includes genetics and neurological insults. Treatment of OCD includes psychotherapy, pharmacotherapy, electroconvulsive therapy, transcranial magnetic simulation, and in extreme cases surgery. Exposure and response prevention is the most effective form of psychotherapy. Selective serotonin reuptake inhibitors (SSRIs) are the preferred pharmacotherapy. Higher doses than listed in the package insert and a longer trial are often needed for SSRIs than compared to other psychiatric disorders. Alternatives to SSRIs include clomipramine and serotonin/norepinephrine reuptake inhibitors. Treatment of resistant cases includes augmentation with atypical antipsychotics, pindolol, buspirone, and glutamate-blocking agents.

Entities:  

Keywords:  exposure and response prevention; obsessive–compulsive disorder; psychiatry; psychopharmacology; serotonin reuptake inhibitors

Mesh:

Substances:

Year:  2014        PMID: 24576790     DOI: 10.1177/0897190014521996

Source DB:  PubMed          Journal:  J Pharm Pract        ISSN: 0897-1900


  18 in total

1.  Activation of serotonin 5-HT2A receptors inhibits high compulsive drinking on schedule-induced polydipsia.

Authors:  Silvia Victoria Navarro; Valeria Gutiérrez-Ferre; Pilar Flores; Margarita Moreno
Journal:  Psychopharmacology (Berl)       Date:  2014-08-26       Impact factor: 4.530

Review 2.  Second generation antipsychotic-induced obsessive-compulsive symptoms in schizophrenia: a review of the experimental literature.

Authors:  Trehani M Fonseka; Margaret A Richter; Daniel J Müller
Journal:  Curr Psychiatry Rep       Date:  2014-11       Impact factor: 5.285

Review 3.  Restricted, Repetitive Behaviors in Autism Spectrum Disorder and Obsessive-Compulsive Disorder: A Comparative Review.

Authors:  Marina Jiujias; Elizabeth Kelley; Layla Hall
Journal:  Child Psychiatry Hum Dev       Date:  2017-12

Review 4.  The importance of the excitatory amino acid transporter 3 (EAAT3).

Authors:  Walden E Bjørn-Yoshimoto; Suzanne M Underhill
Journal:  Neurochem Int       Date:  2016-05-24       Impact factor: 3.921

5.  Developmental emergence of an obsessive-compulsive phenotype and binge behavior in rats.

Authors:  Nadja Freund; Britta S Thompson; Kevin J Norman; Patrick Einhorn; Susan L Andersen
Journal:  Psychopharmacology (Berl)       Date:  2015-05-29       Impact factor: 4.530

6.  Gray and white matter volume abnormalities in generalized anxiety disorder by categorical and dimensional characterization.

Authors:  Kevin Hilbert; Daniel S Pine; Markus Muehlhan; Ulrike Lueken; Susann Steudte-Schmiedgen; Katja Beesdo-Baum
Journal:  Psychiatry Res       Date:  2015-10-13       Impact factor: 3.222

Review 7.  Neurobiology of rodent self-grooming and its value for translational neuroscience.

Authors:  Allan V Kalueff; Adam Michael Stewart; Cai Song; Kent C Berridge; Ann M Graybiel; John C Fentress
Journal:  Nat Rev Neurosci       Date:  2015-12-17       Impact factor: 34.870

Review 8.  Possible actions of cannabidiol in obsessive-compulsive disorder by targeting the WNT/β-catenin pathway.

Authors:  Alexandre Vallée; Yves Lecarpentier; Jean-Noël Vallée
Journal:  Mol Psychiatry       Date:  2021-04-09       Impact factor: 15.992

9.  Is orthorexia nervosa a feature of obsessive-compulsive disorder? A multicentric, controlled study.

Authors:  G Vaccari; A Cutino; F Luisi; N Giambalvo; S Navab Daneshmand; M Pinelli; G Maina; G M Galeazzi; S Kaleci; U Albert; A R Atti; S Ferrari
Journal:  Eat Weight Disord       Date:  2021-02-05       Impact factor: 4.652

10.  Intravenous Clomipramine for Treatment-Resistant Obsessive-Compulsive Disorder.

Authors:  Wael Karameh Karameh; Munir Khani
Journal:  Int J Neuropsychopharmacol       Date:  2015-07-28       Impact factor: 5.176

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.